Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels

Anesthesia and Analgesia

Volumn 84, Issue 5, 1997, Pages 1038-1041

  Weglinski, Margaret R ^a,b   Wedel, Denise J ^a   Engel, Andrew G ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CREATINE KINASE; HALOTHANE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CONTRACTURE; PRIORITY JOURNAL; VASTUS LATERALIS MUSCLE;

EID: 0030909759     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-199705000-00016     Document Type: Article

References (16)

1. Lingaraju N, Rosenberg H. Unexplained increases in serum creatine kinase levels: its relation to malignant hyperthermia susceptibility. Anesth Analg 1991;72:702-5.
2. Gronert GA. Muscle contractures and adenosine triphosphate depletion in porcine malignant hyperthermia. Anesth Analg 1979;58:367-71.
3. Larach MG. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989;69:511-5.
4. Britt BA, Endrenyi L, Peters PL, et al. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can Anaesth Soc J 1976;23:263-84.
5. McPherson E, Taylor CA, Jr. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet 1982;11:273-85.
6. Ellis FR, Clarke IMC, Modgill M, et al. Evaluation of creatine phosphokinase in screening patients for malignant hyperpyrexia. BMJ 1975;3:511-3.
7. Paasuke RT, Brownell AKW. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. JAMA 1986;255:769-71.
8. Amaranath L, Lavin TJ, Trusso RA, Boutros AR. Evaluation of creatinine [sic] phosphokinase screening as a predictor of malignant hyperthermia. Br J Anaesth 1983;55:531-3.
9. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991;338:1491-2.
10. Birmingham PK, Stevenson GW, Uejima T, Hall SC. Isolated postoperative myoglobinuria in a pediatric outpatient: a case of malignant hyperthermia. Anesth Analg 1989;69:846-9.
11. Poels PJE, Joosten EMG, Sengers RCA, et al. In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis. J Neurol Sci 1991;105:67-72.
12. Larach MG. Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility? Anesthesiology 1993;79:1-4.
13. Braude BM, Press P, Moyes DG, et al. Unexpected hyperthermia manifesting during outpatient anesthesia. Anesthesiology 1986; 64:647-50.
14. Levitt RC, Nouri N, Jedlicka AE, et al. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991;11:543-7.
15. Hogan K, Couch F, Powers PA, Gregg RG. A cysteine-forarginine substitution (R614C) in the human skeletal muscle calcium release channel cosegregates with malignant hyperthermia. Anesth Analg 1992;75:441-8.
16. Heiman-Patterson TD, Rosenberg H, Fletcher JE, Tahmoush AJ. Halothane-caffeine contracture testing in neuromuscular diseases. Muscle Nerve 1988;11:453-7.